Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,207 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Powder Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Chokeberry to Reduce Cardiovascular Disease Risk in Former Smokers

NCT01541826
View directory record Official record
Conditions
Cardiovascular Disease, Oxidative Stress
Interventions
Chokeberry Extract, Placebo capsule, Chokeberry extract capsule, acute
Dietary Supplement
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 30, 2026, 7:50 AM EDT
Recruiting Phase 4 Interventional

A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag

NCT07759804
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
LIQ861 (treprostinil) inhalation powder
Combination Product
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 7:50 AM EDT
Terminated Phase 1 Interventional

Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)

NCT03116971
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
M3814, Cisplatin, Etoposide
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
16
States / cities
Mesa, Arizona • Santa Rosa, California • Whittier, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

NCT03387852
View directory record Official record
Conditions
Asthma
Interventions
SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
18
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 30, 2026, 7:50 AM EDT
Terminated Phase 2 Interventional Results available

Rapid Antidepressant Effects of Leucine

NCT03079297
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
L-Leucine, Maltodextrin
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Trial of Two Study Drinks in Detoxification of Environmental Toxicants and Carcinogens

NCT03978117
View directory record Official record
Conditions
Healthy
Interventions
Freeze Dried Watercress Preparation, Placebo Preparation
Dietary Supplement
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 1 Interventional

Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks

NCT01405391
View directory record Official record
Conditions
Major Advanced Solid Tumors Other Than Colorectal
Interventions
PM01183
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Aurora, Colorado • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 2 Interventional Results available

Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

NCT04266197
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)
Combination Product
Lead sponsor
Respira Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 4 Interventional Results available

Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02786927
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo ELLIPTA device, Placebo capsules for use in HANDIHALER device, Inhaler Preference Questionnaire Version 1, Inhaler Preference Questionnaire Version 2
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
22
States / cities
Glendale, Arizona • Clearwater, Florida • Orlando, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 30, 2026, 7:50 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

NCT01875003
View directory record Official record
Conditions
Asthma
Interventions
Lebrikizumab, Placebo, Standard of Care
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 17 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
16
States / cities
Mission Viejo, California • Stockton, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults

NCT04015479
View directory record Official record
Conditions
Aging, Sarcopenia
Interventions
Peanut Protein Powder, Full body resistance training
Dietary Supplement · Behavioral
Lead sponsor
Auburn University
Other
Eligibility
50 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 1Phase 2 Interventional

Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence

NCT03015246
View directory record Official record
Conditions
Heroin Dependence, Opioid Use Disorder
Interventions
Extended release morphine, Buprenorphine/Naloxone low dose, Buprenorphine/Naloxone moderate dose, Buprenorphine/Naloxone high dose, Active stressor, Placebo stressor
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 30, 2026, 7:50 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Effect of Blueberries on Enhancing Insulin Sensitivity in Humans: A Pilot Study

NCT01005420
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Blueberry Powder, Placebo
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer

NCT00117286
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
17
States / cities
Homewood, Alabama • Anaheim, California • Tarzana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 2 Interventional Results available

Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

NCT01956669
View directory record Official record
Conditions
Solid Tumours
Interventions
Pazopanib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
24
States / cities
Long Beach, California • Madera, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 30, 2026, 7:50 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

NCT05830097
View directory record Official record
Conditions
Cancer, Breast, Cancer, Lung, Cancer of Pancreas, Cancer of Esophagus, Cancer Colorectal
Interventions
CBP-1019
Drug
Lead sponsor
Coherent Biopharma (Hefei) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Cerritos, California • Orlando, Florida • Manhasset, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

NCT04530123
View directory record Official record
Conditions
Celiac Disease
Interventions
Placebo, TAK-101, Gluten
Drug · Dietary Supplement
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
26
States / cities
Scottsdale, Arizona • Escondido, California • Poway, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children

NCT00528957
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir DF, Zidovudine, Stavudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 15 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
6
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Oral Immunotherapy for Wheat Allergy

NCT01980992
View directory record Official record
Conditions
Wheat Allergy
Interventions
Wheat OIT
Drug
Lead sponsor
Hugh A Sampson, MD
Other
Eligibility
4 Years to 30 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Stanford, California • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Influence of Freeze Dried Strawberry Consumption on Gut Microbiota and Cardiovascular Health.

NCT03283969
View directory record Official record
Conditions
Microbial Colonization, Cardiovascular Diseases, Obesity
Interventions
Freeze Dried Strawberry Powder, Isocaloric powder
Other
Lead sponsor
University of California, Davis
Other
Eligibility
40 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures

NCT01913405
View directory record Official record
Conditions
Hemophilia A
Interventions
PEGylated Recombinant factor VIII (rFVIII)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Gainesville, Florida • Peoria, Illinois • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

NCT03580356
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab, Omalizumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,078 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
34
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 30, 2026, 7:50 AM EDT
Terminated Phase 1 Interventional

Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma

NCT02163356
View directory record Official record
Conditions
Recurrent Neuroblastoma, Neuroblastoma
Interventions
Fenretinide/LXS Oral Powder, Ketoconazole, Vincristine
Drug
Lead sponsor
South Plains Oncology Consortium
Network
Eligibility
Up to 30 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Chicago, Illinois • Dallas, Texas • Fort Worth, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 30, 2026, 7:50 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants

NCT04131556
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Maribavir
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 30, 2026, 7:50 AM EDT